USA flag logo/image

An Official Website of the United States Government

Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
C2-0349
Solicitation Year:
2010
Solicitation Topic Code:
CBD10-109
Solicitation Number:
2010.1
Small Business Information
IMPEL NEUROPHARMA, INC.
867 SW SHOREMONT AVE NORMANDY PARK, WA 98166-3645
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents
Agency: DOD
Contract: W81XWH-10-C-0238
Award Amount: $749,641.00
 

Abstract:

Technical Abstract Impel NeuroPharma has developed a novel non-invasive delivery system, the POD device that targets drug to the upper third of the nasal cavity which results in direct and rapid transport of drug to the CNS via the olfactory perineural pathways, effectively bypassing the BBB. In Phase I of this research contract Impel successfully characterized and tested both an aqueous and a dry powder form of 2-PAM for administration via Impel"s POD device, which led to dramatic increases in 2-PAM brain concentrations and lower plasma concentrations compared to IV administration. In Phase 2 of this research contract, Impel will conduct critical studies in order to ready this product for clinical trials and ultimately for use in the battlefield setting as an effective treatment for nerve gas exposure. Impel"s four main objectives are 1) Determine doses of POD administered 2-PAM and MMB-4 with optimal CNS exposure in rats; 2) Demonstrate the CNS protective effects of POD administered 2-PAM and MMB-4 in rats exposed to the nerve agents sarin and soman; 3) Develop optimized POD device for battlefield oxime use; and 4) Determine tolerability and drug distribution of POD administered oxime in non-human primates.

Principal Investigator:

John Hoekman
Chief Scientific Officer
(206) 568-1466
hoekman@impelneuropharma.com

Business Contact:

Michael Hite
Chief Executive Officer
(206) 697-5817
hite@impelneuropharma.com
Small Business Information at Submission:

Impel NeuroPharma
867 SW Shoremont Ave Normandy Park, WA -

EIN/Tax ID: 263058238
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No